학술논문
Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study.
Document Type
Article
Author
Belhadj, Maya; Burroni, Barbara; Kosmider, Olivier; Willems, Lise; Temple, Marie; Bertoli, Sarah; Orvain, Corentin; Dumas, Pierre‐Yves; Berthon, Celine; Gabellier, Ludovic; Marcais, Ambroise; Raffoux, Emmanuel; Pautas, Cecile; Genthon, Alexis; Decroocq, Justine; Birsen, Rudy; Tamburini, Jerome; Bouscary, Didier; Contejean, Adrien
Source
Subject
*MYELOID sarcoma
*BLAST injuries
*CHRONIC myeloid leukemia
*ACUTE myeloid leukemia
*PROGNOSIS
*SCIENTIFIC observation
*SYNOVIOMA
*
*
*
*
*
*
Language
ISSN
0007-1048
Abstract
Previous studies of MS have reported a CR rate of 45%-70% after IC and median OS of 12.8-15.9 months.[[11], [13]] Our multi-variate Cox model showed that an age >65 years, a BM blast rate >=20% and patients with refractory or relapsing disease were independently associated with mortality. Myeloid sarcoma (MS) accounts for 3%-8% acute myeloid leukaemia (AML) cases and is characterized by an extramedullary proliferation of myeloid blast cells forming a solid tumour,[1] with or without bone marrow (BM) involvement.[[2]] A history of other myeloid neoplasms can precede MS occurrence.[4] MS literature is scarce with mostly heterogeneous cohorts mixing primary MS with extramedullary AML relapses. Patients with extramedullary AML relapses and with no MS at their first AML diagnosis were excluded, but patients with a history of MDS/MPN were eligible. The median OS was not reached for patients with a bone marrow (BM) blast rate <20% versus 24 months for patients with a BM blast rate >=20%. [Extracted from the article]